Welcome to our dedicated page for Crescent Biopharma news (Ticker: CBIO), a resource for investors and traders seeking the latest updates and insights on Crescent Biopharma stock.
Crescent Biopharma reports news about its clinical-stage oncology pipeline, including CR-001, a PD-1 x VEGF bispecific antibody, and antibody-drug conjugate programs such as CR-002 and CR-003. Company updates commonly cover clinical trial activity in solid tumors, pipeline combinations, collaboration activity, financial results, and business highlights.
Recurring corporate announcements also include investor conference presentations and equity inducement awards under the company’s employment inducement incentive plan. These updates reflect Crescent’s status as a Nasdaq-listed biotechnology issuer focused on cancer therapeutics.
Catalyst Biosciences (NASDAQ: CBIO) presented four key posters at the ISTH 2021 Virtual Congress from July 17-21, highlighting significant findings on Marzeptacog Alfa (MarzAA) and Dalcinonacog Alfa (DalcA). The studies demonstrated MarzAA's effectiveness in treating bleeding in FVII deficient rats and outlined dosage selection strategies for clinical trials, particularly in children with Hemophilia. Additionally, research into DalcA addressed injection site reactions with optimizations in formulation buffers. Catalyst is advancing MarzAA in Phase 3 and Phase 1/2 trials.
Catalyst Biosciences (NASDAQ: CBIO) has announced key management changes, promoting Grant Blouse, Ph.D., to chief scientific officer and Tom Knudsen, DVM, Ph.D., to senior vice president of corporate development. Howard Levy, M.B.B.Ch, Ph.D., M.M.M., will retire as chief medical officer, transitioning to a senior clinical advisor role. These changes aim to strengthen the leadership team as Catalyst advances its SQ hemophilia programs, including SQ MarzAA and SQ DalcA, now in late-stage clinical trials. The company focuses on rare disorders of the coagulation and complement systems.
Catalyst Biosciences (NASDAQ: CBIO) announced four poster presentations at the International Society on Thrombosis and Haemostasis Virtual Congress from July 17-21, 2021. The presentations will focus on marzaptacog alfa (MarzAA) and dalcinanonog alfa (DalcA), highlighting various dose selection strategies and efficacy in treating bleeding disorders. These insights aim to advance the understanding of their engineered proteases, which target rare coagulation disorders. Access to presentation materials will be available on the Catalyst website once the congress begins.
Catalyst Biosciences (NASDAQ: CBIO) will host an R&D day on July 19, 2021, focusing on its protease medicines platform, particularly CB 4332, which addresses complement disorders. Key speaker, Dr. Filomeen Haerynck, will discuss CFI deficiency and unmet medical needs. Catalyst plans to initiate screening studies for CFI deficiency in mid-2021, leading to a Phase 1/2 study for CB 4332 in 2022. The company’s complement pipeline also includes CB 2782-PEG, in development for dry AMD. Registration for the event is available online.
Catalyst Biosciences announced that the FDA has granted a second Fast Track Designation for Marzeptacog alfa (MarzAA), an engineered coagulation Factor VIIa for treating episodic bleeding in patients with Factor VII deficiency.
This designation allows for expedited development and review, facilitating greater access and priority review by the FDA. Catalyst is currently enrolling patients in a Phase 1/2 open-label study for MarzAA and conducting a Phase 3 registration trial for Hemophilia A or B with inhibitors.
Catalyst Biosciences, Inc. (NASDAQ: CBIO) announced participation in two investor conferences in June 2021, aiming to engage with investors and discuss its pipeline. The JMP Securities Life Sciences Conference is on June 16, 2021, at 1:30 PM ET. A webcast is available here. The Raymond James Human Health Innovation Conference will be on June 23, 2021, at 11:20 AM ET, with a webcast available here. Archived presentations will be available for 90 days.
Catalyst Biosciences (NASDAQ: CBIO) has initiated dosing in its Phase 1/2 trial (MAA-202) for MarzAA, a novel subcutaneous treatment for bleeding disorders including FVII deficiency and Hemophilia A. This open-label study will assess the pharmacokinetics, safety, and efficacy of MarzAA. CEO Nassim Usman emphasized the significance of MarzAA as a unique bypassing agent for rapid bleeding treatment. The ongoing Phase 3 study (MAA-304) complements this effort, targeting hemophilia patients on Hemlibra prophylaxis. Updates on the clinical program are expected later this year.
Catalyst Biosciences (NASDAQ: CBIO) will participate in a fireside chat at the Truist Securities Life Sciences Summit on May 17, 2021, at 1:00 PM ET.
Investors can access a live webcast of the presentation through the company’s website, with an archived version available for 90 days post-event. Catalyst focuses on rare disorders, utilizing its engineered protease platform to develop therapies like MarzAA for bleeding disorders and a preclinical C3-degrader program licensed to Biogen for age-related macular degeneration.
Catalyst Biosciences (NASDAQ: CBIO) reported its financial and operational results for Q1 2021, highlighting advances in their Protease Medicines platform. The company plans to initiate a trial for its CFI deficiency candidate, CB 4332, by mid-2021 and has started dosing patients in the Phase 3 trial of MarzAA for hemophilia. Financially, Catalyst had $107 million in cash but reported a net loss of $22.4 million, significantly higher than the prior year's loss of $4.1 million. Research and development expenses rose 28% to $17 million, largely due to increased preclinical costs.
Catalyst Biosciences, Inc. (NASDAQ: CBIO) has commenced dosing in the Crimson 1 Study, a Phase 3 trial for Marzeptacog alfa (activated) – MarzAA, a subcutaneous treatment for bleeding events in congenital Hemophilia A or B patients with inhibitors. This trial is a pivotal step, especially amid the challenges posed by the COVID-19 pandemic. MarzAA is the only subcutaneously administered therapy in development for this purpose. The study's primary goal is to evaluate the efficacy and safety of MarzAA in episodic bleeding treatment, anticipating updates later this year.